Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of LSCD101 Transplantation for Limbal Stem Cell Deficiency
NCT04773431Phase 1Completed
- Sponsor
- G.CLIPS Biotech
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LSCD101 in limbal stem cell deficiency (LSCD), sponsored by G.CLIPS Biotech. Primary endpoint: Rate of Adverse event at 24 weeks. Started Jan 2020; status: completed.
02
Drugs
LSCD101
03
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on NCT04773431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04773431.